Fcn-437C
Advanced Breast Cancer
Ahon Pharmaceutical Co., Ltd.Phase 3Active
CCC
54/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 73/ 100
Competitive context
52 Active assets in the Advanced Breast Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Camizestrant AstraZeneca | Phase 3 | BB |
tqb3616 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 3 | BB |
Syhx2011 CSPC Ouyi Pharmaceutical Co., Ltd. | Phase 3 | B |
GB491 Genor Biopharma Co., Ltd. | Phase 3 | B |
utd1 Henan Cancer Hospital | Phase 3 | B |
View all 50 →
Same molecule, other indications
Fcn-437C is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →